Revenue: The sum of all revenue fields included for a company's operating activities.
Xeris Biopharma Holdings, Inc. (XERS) had Revenue of $203.07M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$203.07M |
$-54.84M |
|
$36.83M |
|
$166.24M |
|
$236.72M |
|
$-33.65M |
|
$-23.46M |
|
$-57.10M |
|
$-57.10M |
|
$-54.84M |
|
$-54.84M |
|
$-54.84M |
|
$-54.84M |
|
$-33.65M |
|
$-18.01M |
|
146.77M |
|
146.77M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$167.66M |
|
$5.56M |
|
$155.40M |
|
$323.06M |
|
$100.44M |
|
$217.01M |
|
$252.23M |
|
$352.68M |
|
$-29.61M |
|
$-151.40M |
|
$-29.61M |
|
149.43M |
|
| Cash Flow Statement Financials | |
$-36.98M |
|
$4.88M |
|
$36.17M |
|
$71.67M |
|
$75.74M |
|
$4.07M |
|
$18.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.67 |
|
-- |
|
-- |
|
1.16 |
|
-7.84 |
|
81.86% |
|
-16.57% |
|
-16.57% |
|
-8.87% |
|
-28.12% |
|
-27.00% |
|
$-37.85M |
|
-- |
|
-- |
|
-- |
|
0.63 |
|
0.76 |
|
5.02 |
|
72.64 |
|
185.16% |
|
36.22% |
|
-16.97% |
|
-29.26% |
|
$-0.20 |
|
$-0.26 |
|
$-0.25 |
|